Vane Minerals could be producing from its Wate uranium project in Arizona by early 2011 after encouraging drilling results.
So says Matthew Idiens, commercial development director of the London-based company, which has reported drilling intercepts at the Wate breccia pipe including 25.5 feet at 0.47 per cent U3O8 and 25 feet at 0.22 per cent U3O8. Vane, which still derives cash from its original gold and silver operation at Diablito in Mexico, is now primarily focused on uranium and says it hopes to have an industry-standard uranium resource estimate ready by the end of this year.
Idiens points out even this may not tell the full story since ‘there are still 160 targets’ to explore, adding that Canadian miner Denison is going into uranium production next year on federal land in Arizona. Vane, which is a 50-50 partner at Wate with Canada’s Uranium One, says its data so far confirms that compiled years ago by a previous developer, Rocky Mountain Energy.
Floated three years ago at 11p as a gold and silver play, Vane shares hit 32.5p in 2007 but then slumped to 2.25p within the past year. If further studies and the permitting process bear out latest indications, they have scope for further recovery.
Market cap: £11m
PE Forecast: n/a
Share price: 4.88p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.